Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiangsu Zecheng Completes $26 Million Round to Develop Diagnostics

publication date: Aug 1, 2019

Jiangsu Zecheng Biotech completed a $26 million C Round financing to support its in vitro diagnostic business that offers fully automatic chemiluminescence-based tests. The round was led by Hongtai Capital and included Wuxi Capital along with other firms. The funds will be used for R&D of new products and platform improvements. Zecheng Bio's devices and reagents have been approved in China and the EU. Established in 2011, Zecheng sells its devices to secondary and tertiary hospitals in China and markets them in Asia, Latin America, Eastern Europe and Southern Europe. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital